Articles written by SciSparc - Benzinga

SciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller Brand

TEL AVIV, Israel, Dec. 14, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd.

SciSparc Gains Competitive Edge with Additional U.S. Patent Granted

This patent extends protection, adding to six other U.S. patents already granted

SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer's Disease Patients with Agitation

Meets primary endpoints- SCI-110 administration was found to be safe at all tested doses SCI-110 treatment was also found to reduce agitation - 75% of patients did not need to use additional medication to control agitation and 75% of patients experienced increased appetite

SciSparc Completes the Acquisition of Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million

Wellution™ offers dozens of products including natural supplements, creams, gels and hemp-based products on Amazon.com Marketplace

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic Syndromes

TEL AVIV, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that Clearmind Medicine Inc.

SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.

Results indicate significant decrease in cocaine craving in a sub-group that received the treatment

SciSparc Issued Israeli Patent For Its Core Technology For Treating Central Nervous Systems Disorders

Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan

SciSparc Successfully Completed The Development Of Its Proprietary Drug Candidate SCI-110 For Its Upcoming Phase IIb Study In Tourette Syndrome

TEL AVIV, Israel, June 29, 2022 /PRNewswire/ -- SciSparc Ltd.

SciSparc Announces Ethics Committee Approval To Conduct Its Clinical Trial In Autism Spectrum Disorder

The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment

SciSparc Reinforces Its New JV For Targeting Discovery With A Global Expert In The Field Of Mitochondrial Transport Proteins

JV Targets Potential Drugs for Cancers and Infectious Diseases

SciSparc Ltd. Announces Initial Positive Results For The Cocaine Addiction Treatment Of Clearmind Medicine Inc.

SciSparc and Clearmind recently announced the filing of a patent application related to treating cocaine addiction

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction

No dedicated treatment currently available for cocaine addiction

SciSparc To Collaborate With Polyrizon For Brain Targeting Using Intranasal Hydrogel Systems

SciSparc will use its SCI-160 technology platform for treating pain in combination with Polyrizons' Trap and TargetTM technology

SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial In Tourette Syndrome

Ethics Committee approval received from the two sites that will conduct the SCI-110 trial in Germany and Israel

SciSparc And Clearmind Medicine Inc. Collaboration Yields Positive Results For Its Psychedelic Combination Treatment

Pre-clinical trials based on the proprietary combination demonstrate significant suppressive effect on alcohol consumption

SciSparc And Clearmind Medicine Inc. Collaboration Yields New Patent Application For Psychedelic Combination Treatment For Binge Behaviors

Preclinical study results demonstrated the combination of SciSparc's CannAmide™ with Clearmind's MEAI has the potential to reduce alcohol consumption

SciSparc Files Annual Report For Year Ended December 31, 2021 And Provides Corporate Update

TEL AVIV, Israel, May 2, 2022 /PRNewswire/ -- SciSparc Ltd.